Espicom


The Pharmaceutical Market: Gabon

Published 31 October 2014

  • 47 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
The Pharmaceutical Market: Gabon

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
12
Industry Forecast
13
Pharmaceutical Market Forecast
13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Gabon 2010-2018)
14
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Gabon 2010-2018)
17
Industry Risk Reward Indicies
18
Middle East & Africa Risk/Reward Index
18
Gabon Risk/Reward Index
25
Rewards
25
Risks
25
Market Overview
26
Industry Trends And Developments
28
Epidemiology
28
Regulatory Development
31
Competitive Landscape
33
Pharmaceutical Sector
33
Demographic Forecast
36
Demographic Outlook
36
Table: Gabon's Population By Age Group, 1990-2020 ('000)
37
Table: Gabon's Population By Age Group, 1990-2020 (% of total)
38
Table: Gabon's Key Population Ratios, 1990-2020
39
Table: Gabon's Rural And Urban Population, 1990-2020
39
Glossary
40
Methodology
42
Pharmaceutical Expenditure Forecast Model
42
Healthcare Expenditure Forecast Model
42
Notes On Methodology
43
Risk/Reward Index Methodology
44
Index Overview
45
Table: Pharmaceutical Risk/Reward Index Indicators
45
Indicator Weightings
46
OVERVIEW OF THE PHARMACEUTICAL MARKET IN GABON

There are emerging downside risks to our Gabon pharmaceutical and healthcare expenditure forecasts. Economic expansion is stagnating, which could lead to political instability. The country's much-praised universal healthcare system is undergoing reforms, and the infectious disease burden remains intractably high. Commercial opportunities in the medical sector will be limited to low-value, moderate-volume generic drugs and very low-volume, high - value branded medicines.

Headline Expenditure Forecasts

Pharmaceuticals: XAF67.7bn (US$131mn) in 2012 to XAF72.0bn (US$137mn) in 2013; +6.4% in local currency and 5% in US dollar terms. Market size and forecast revised down compared with Q113 update due to new historic data and a less optimistic macroeconomic outlook.

Healthcare: XAF286bn (US$551mn) in 2012 to XAF303bn (US$577mn) in 2012; +6.0% in local currency and +3.0% in US dollar terms. Market size and forecast revised down compared with Q113 update due to new historic data and a less optimistic macroeconomic outlook.

Risk/Reward Rating

Gabon's Pharmaceutical Risk/Reward Rating (RRR) score for Q213 is unchanged from the previous quarter. This is also the case for all other countries in BMI ' s proprietary system , which ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in the Q313 updates of the Pharmaceuticals & Healthcare reports. Gabon has a RRR score of 40. 0 out of 100, m making it the 20th most attractive pharmaceutical market in the Middle East and Africa.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%